Detection of Human Pegivirus (HPgV) infection among Filipino children with decompensated liver disease secondary to biliary Cirrhosis and liver transplant pediatric patients

Background@#Human Pegivirus (HPgV), previously called Hepatitis G virus or GB virus C, is an RNA virus. It can be transmitted vertically (mother to infant), parenterally and sexually. HPgV share common routes of transmission to other viruses such as Hepatitis B virus, Hepatitis C virus and Human Immunodeficiency virus (HIV) thus co-infection is usually observed. Risk groups of HPgV include injection drug users, HIV-positive individuals, multi-transfused patients, hemodialysis patients, hemophiliacs, chronic liver disease patients and organ transplant recipients. The clinical significance of HPgV is not yet established and warrants further studies. Research on HPgV in the Philippines is scarce and has not been updated for over 10 years. There is no published data on HPgV prevalence in Filipino pediatric population specifically among risk groups like multi-transfused children with decompensated liver disease secondary to biliary cirrhosis and liver transplant pediatric patients. The lack of local data warrants conduct of this study. @*Objective@#To determine the presence of HPgV RNA, HPgV E2 antibody (anti-E2) and HBsAg among Filipino children with decompensated liver disease secondary to biliary cirrhosis (DBC) and liver transplant pediatric patients (LTP).@*Methods@#Included were 15 children with DBC and 15 LTP recruited from the Section of Pediatric Gastroenterology, Hepatology and Nutrition of the UP PGH. All patients’ sera were tested for HPgV RNA by Real Time RT-PCR, HPgV anti-E2 by Enzyme-linked Immunosorbent Assay (ELISA) and hepatitis B surface antigen (HBsAg) by immunochromatographic test. Twenty age and sex matched children with no history of liver disease and blood transfusion served as controls. @*Results@#All patient and control samples were negative for HPgV RNA. HPgV anti-E2 was detected in 6 of 15 LTP, 5 of 15 DBC and 1 of 20 controls. HBsAg was detected in 2 of 15 LTP, 5 of 15 DBC and 0 of 20 controls. Four patients (two LTP, two DBC) were positive for both HPgV anti-E2 and HBsAg. @*Conclusion@#This study showed that a proportion of liver transplant patients and those with decompensated biliary cirrhosis are positive for HPgV anti-E2, which indicates that these individuals previously had HPgV infection but is now resolved. Possible source of infection is infected blood from the blood transfusions, infected transplant organ or infected mother. Since routine HPgV screening is not yet recommended for the general population, blood donors and organ donors, the confirmation of exact source of infection may be difficult. Co-infection with HBsAg was also observed in both risk groups which suggests that at some point in time, these children were infected by both HPgV and HBV and also the possibility of simultaneous infection by the two viruses. This study provides preliminary data on the proportion of HPgV infection in Filipino children belonging to two of the HPgV risk groups. Studies with a larger and more significant sample size to determine HPgV prevalence as well as studies regarding the pathogenicity of HPgV are warranted. As this may provide basis for routine HPgV screening among risk groups and blood donations in the future.

Prevalence of Transfusion Transmitted Infections in Multiple Blood Transfused β-Thalassemia Patients from a Tertiary Care Centre in North India

Introduction: The mainstay of therapy for patients sufferingfrom beta thalassemia major is regular blood transfusionand chelation therapy due to constraints in bone marrowtransplantation. The present study was conducted to estimatethe prevalence of transfusion-transmitted infections (TTIs)in multitransfused patients of thalassemia major and todetermine the association with relation to the number of bloodtransfusions received.Material and Methods: This study was conducted inDepartment of Microbiology on 126 β- thalassemiamajor patients registered for regular blood transfusions atThalassemia Day Care Centre attached to Department ofPediatrics, Government Medical College, Amritsar, Punjabfrom January to July 2018. The patient’s serum sampleswere screened for TTIs i.e. Human Immunodeficiency Virus(HIV), Hepatitis B virus (HBV) and Hepatitis C virus (HCV).Seropositivity screening for HBV and HCV was done by rapidImmunochromatographic test and confirmed by enzymelinked immunosorbent assays. (ELISA) while for HIV as perNACO guidelines.Results: Out of 126 patients, 14.28% (18/126) were seroreactive for TTIs. Of these sero-reactive patients, 13.4%(17/126) were positive for anti-HCV antibody, 0.79% (1/126)positive for HBsAg and none (0) for anti HIV antibody. Ofthe anti-HCV reactive cases, 70.5% (12 out of 17) were>12years of age, 58.8% (10 out of 17) had received morethan 250 transfusions, and 23.5% (4 out of 17) had receivedtransfusions between 100 to 250. Anti-HCV seroreactivitywas thus found to increase with the age and increase in thenumber of transfusions received.Conclusion: It is concluded that HCV is the most prevalentTTI in multi-transfused children with thalassemia major andstringent pre-transfusion screening of blood for anti-HCVmust be introduced in blood centers. HBV vaccination shouldalso be done before the start of transfusion regimen or as soonas possible after diagnosis of thalassemia.

Comparative study of alloimmunization against red cell antigens in sickle cell disease & thalassaemia major patients on regular red cell transfusion

Background & objectives: Sickle cell disease (SCD) patients require red cell transfusion during different clinical complications of the disease. Such patients are at a high risk for developing alloantibody against red cell antigens. From India, there are limited data available on alloantibody formation in multiply transfused SCD patients. The present study was thus undertaken to fill up this lacunae by looking at the development of red cell alloantibodies in SCD and ?-thalassaemia patients on regular transfusion. Methods: All sickle cell disease patients undergoing red cell transfusion between 2008 and 2016, were included. During this period, a large number of ?-thalassaemia major patients also underwent regular red cell transfusion. These thalassaemia patients were also included to compare the tendency of antibody formation between SCD and ?-thalassaemia major patients. All patients before regular transfusion were regularly assessed for the development of red cell antibody. Red cell antigen, antibody screen crossmatch and antibody identification were done using the standard technique. Results: A total of 138 patients with SCD aged between 4 and 53 yr (mean 17.6 yr) consisting of 83 males and 55 females (male:female, 1.5:1) along with 333 transfusion-dependent ?-thalassaemia patients were studied. Over the last eight years, 15 patients with SCD and four patients with thalassaemia developed alloantibody (P <0.001). Antibody specificity of their alloantibodies was against Rhc, RhE, Kell, Fya and Fyb only. Sickle cell disease patients with and without alloantibody required on the average 11.8 and 8.6 units of red cell concentrate, respectively (P <0.05). Interpretation & conclusions: About 11 per cent of the transfused sickle cells patients developed alloantibodies. The antibody specificity was restricted to Rh, Kell and Duffy blood group systems. Extended antigen matching involving Rh, Kell and Duffy antigens may prevent alloantibody in such patients.

Clinical and epidemiological profile of alloimmunized and autoimmunized multi-transfused patients against red blood cell antigens in a blood center of Minas Gerais

ABSTRACT Background: The large diversity of red blood cell antigens favors, especially in multi-transfused patients, the occurrence of autoimmunization and alloimmunization with the risk of hemolytic transfusion reactions. Thus, this study aimed to determine the rates of alloimmunization and autoimmunization in these individuals, as well as the types of alloantibodies and their systems, clinical and epidemiological aspects and the frequency of autoimmunity in alloimmunized and non-alloimmunized patients. Methods: In a retrospective study, 153 multi-transfused patients from 2006 to 2014 were evaluated. Sixty-eight had onco-hematological diseases, 64 had hemoglobinopathies and 21 had chronic renal failure. Descriptive analyses were carried out with the proportions being compared using the chi-square test, with the significance level set at 5%. Results: The Rh system was the most frequently involved (53.11%) and anti-E and anti-K (Kell system) were the most prevalent alloantibodies (21.87% each). Autoantibodies were found in ten patients (6.54%) with the percentages of autoimmunization in alloimmunized and non-alloimmunized individuals being 29.16% and 2.32%, respectively (p = 0.0001). There was a significant difference between autoimmunization and the number of transfusions (16.21% in 6-10 vs. 5.26% <6 vs. 2.56% >10; p = 0.0203) and diseases (19.04% in chronic renal failure vs. 6.25% in hemoglobinopathies vs. 2.94% in onco-hematological diseases; p = 0.0329). Conclusion: The results show a strong correlation between alloimmunization and autoimmunization. Moreover, they reinforce the need for further studies on the clinical and epidemiological profile of multi-transfused patients in relation to alloimmunity and autoimmunity, especially the latter, for a better understanding of its etiopathogenesis and physiopathogenesis.

Antibody screening & identification in the general patient population at a tertiary care hospital in New Delhi, India.

Background & objectives: The development of alloantibodies can significantly complicate transfusion therapy and results in difficulties in cross-matching of blood. Most literature on alloimmunization is limited to multitransfused individuals, with very few studies on the general hospital patients. This study was aimed at assessing the frequency and type of unexpected red cell antibodies in the general patient population at a multispecialty tertiary care centre in New Delhi, India. Methods: The results of 49,077 antibody screening tests carried out on patients, from January 2009 to December 2012 were analyzed. The clinical and transfusion records were reviewed. The data were compiled and statistically analysed. Results: A total of 49,077 (29,917; 60.96% males and 19,160; 39.04% females) patient samples were screened for the presence of unexpected antibodies. Antibody screening was positive in 403 patients (0.82%). In the serum samples of 164 patients only autoantibodies were identified, 27 revealed autoantibodies with one or more underlying alloantibodies, while 212 patients had only alloantibody/ies in their serum. The overall alloimmunization rate was 0.49 per cent. Antibodies against the Rh system were the most frequent (64.1%), the most common alloantibody identified being anti E (37.2%), followed by anti D (19.2%). Interpretation & conclusions: Since clinically significant antibodies are frequently detected in our patient population, antibody screening and if required, identification is the need of the hour. Since antibodies against the common Rh and Kell blood group antigens are the most frequent, provision of Rh and Kell matched red cells may be of protective value.

“Seroprevalence of transfusion associated hepatitis c virus (Hcv) in multi-transfused thalassemic children of the tertiary care hospital.”

Aim: To know the seroprevalence of Hepatitis C Virus (HCV) in Multi-transfused Thalassemic Children attending a tertiary care hospital, Ahmedabad, Gujarat. Material and Methods: Serum sample were tested by Enzyme Linked Immuno Sorbent Assay (ELISA) test for Anti HCV antibody from the thalassemic children over a period of 4 years from January 2006 to December 2009. Result: A total of 163 thalassemic children were tested for antibody of HCV. Out of these HCV antibodies were positive in 38 (23.31 %) patients. Conclusion: Prevalence of HCV infection among the thalassemic cases is much higher than the routine blood donors. in the light of this result a nationwide survey is recommended to confirm this pattern in the other areas and more sophisticated diagnostic tool should be employed to rule out window period of these Transfusion Associated infections.

Freqüência de anticorpos irregulares em politransfundidos no Hemocentro Regional de Uberaba-MG, de 1997 a 2005 / Frequency of irregular antibodies in multiple-transfused patients at the Regional Blood Bank of Uberaba, from 1997 to 2005

A fenotipagem eritrocitária pré-transfusional é um importante procedimento para aumentar a segurança das transfusões sangüíneas, sendo realizada rotineiramente no Hemocentro Regional de Uberaba-MG (HRU) desde 1996. O presente trabalho tem como objetivo geral avaliar a freqüência de anticorpos antieritrocitários irregulares em politransfundidos, de 1997 a 2005. Através de estudo retrospectivo foram levantados dados no arquivo do HRU de todos os pacientes aloimunizados, realizou-se análise estatística descritiva e comparam-se as proporções pelo teste "Z". Dos 23.220 transfundidos no período, com média de 5,7 transfusões por paciente, observou-se a ocorrência de aloimunização em 173 (0,75 por cento). Os sistemas Rh e Kell juntos tiveram freqüência superior a 70 por cento. A proporção do anti-D foi significativamente maior nas mulheres (p<0,05) e não houve diferença no sistema Rh entre brancos e não-brancos. Quanto à faixa etária, 70 por cento tinham mais de 30 anos. Dos 73 pacientes que tiveram a doença de base registrada, 39,73 por cento eram portadores de anemias agudas, 31,51 por cento de anemias crônicas e 28,77 por cento de doenças oncológicas ou onco-hematológicas. Aproximadamente 70 por cento dos anticorpos foram identificados até a décima transfusão. A baixa ocorrência da aloimunização no HRU reforça a importância da fenotipagem eritrocitária para todos os pacientes dependentes de transfusões crônicas, bem como da sua implantação na rotina de todos os serviços de hemoterapia.

Testing of the pre-transfusional blood phenotype, which has been carried out at the Regional Blood Bank in Uberaba since 1996, is an important procedure to improve safety of blood transfusions. This study aims to describe the frequency of irregular red blood cell antibodies in multiple-transfused patients from 1997 to 2005. In a retrospective study, data from all alloimmunized patients were collected from the blood bank files. Descriptive statistical analysis was performed and a comparison of proportions was made using the Z test. Alloimmunization was observed in 173 (0.75 percent) of the 23,220 transfused patients, with an average of 5.7 transfusions per patient. The frequency of the Rh and Kell systems jointly was over 70 percent. The proportion of anti-D was significantly higher in women (p<0.05) and no difference was noted in the Rh system between Caucasians and non-Caucasians. Seventy percent (70 percent) of the patients were over 30 years of age. Out of the 73 patients with registered diseases, 39.73 percent had acute anemias, 31.51 percent chronic anemias and 28.77 percent oncological or onco-hematologic diseases. Approximately 70 percent of antibodies were discovered before the 10th transfusion. The low frequency of alloimmunization observed at the Regional Blood Bank of Uberaba reinforces the importance of pre-transfusional blood phenotype screening for all multiple-transfused patients as well as its adoption as a common practice in all hemotherapy center.